Medtronic Website Promotes Activa For Off-Label Uses - FDA Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Medtronic and FDA are continuing discussions about appropriate disclaimers for promotional material on the firm's website related to uses of its Activa tremor control system that are not yet approved in the U.S., following receipt of a March 23 warning letter.
You may also be interested in...
Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer
Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer
Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer
Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer
Internet Promotion Warning Letters Continue In Guidance Vacuum
Counsel for OmniCorder Technologies is preparing a response to an April 18 warning letter citing Internet promotions representing the firm's BioScan system "as a stand-alone diagnostic device for breast cancer detection," the company says.